Thursday, February 14, 2013- A Pipeline Worth Buyingat Motley Fool (Thu, Feb 14)
- Ram Selvaraju: Fall In Love With These Biotech Stocksat Seeking Alpha (Thu, Feb 14)
- Will Pfizer Help You Retire Rich?at Motley Fool (Thu, Feb 14)
- Is Diversification Good or Bad?at Motley Fool (Thu, Feb 14)
- Which Company Will Rule This Multibillion-Dollar Market?at Motley Fool (Thu, Feb 14)
- Agilent Unit & Pfizer CollaborateZacks (Thu, Feb 14)
- The Next Stock You Should Considerat Motley Fool (Thu, Feb 14)
- Nestle makes $11.55 billion profit in 2012AP (Thu, Feb 14)
- Insurance Exchanges are On Track, Health Official Saysat Bloomberg (Thu, Feb 14)
- Hedge Fund Kahn Brothers’ Stock Picks for 2013at Motley Fool (Thu, Feb 14)
- Merck To Pay $688 Million To Shareholders For Delaying Vytorin Resultsat Forbes (Thu, Feb 14)
- Nestle Expects Challenging 2013 as Emerging Markets Slowat Bloomberg (Thu, Feb 14)
- Pfizer Financial Projection And Stock Valuationat Seeking Alpha (Thu, Feb 14)
- BRIEF-Nestle working on divestments after Pfizer buy-CFOat Reuters (Thu, Feb 14)
Wednesday, February 13, 2013- Teva warns could face legal costs of $2.07 blnat Reuters (Wed, Feb 13)
- Pfizer to Novartis Seen Gaining as Drought Ends: Healthat Bloomberg (Wed, Feb 13)
- SAC Probe Said to Be Hampered by Auto-Deleted E-Mailsat Bloomberg (Wed, Feb 13)
- Is the Pharma Industry Facing Pharmageddon?at Motley Fool (Wed, Feb 13)
- Lundbeck Could Cheer Up Patient Investorsat Seeking Alpha (Wed, Feb 13)
- FDA Safety Regs Faulted for Lax Oversightat Forbes (Wed, Feb 13)
- The Most Trustworthy Drugs on the Marketat Motley Fool (Wed, Feb 13)
- [video] Dividend Corner: Live Twitter Chatat TheStreet (Wed, Feb 13)
- Can This Blockbuster Drug Continue to Grow?at Motley Fool (Wed, Feb 13)
- Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefitat TheStreet (Wed, Feb 13)
- This Obesity Bet Just Became More Attractiveat Motley Fool (Wed, Feb 13)
Add PFE News to My Yahoo!   | |
|
0.30(1.02%) 3:59PM EDT|After Hours
:
29.14